>
Switch to:

Guardant Health PS Ratio

: 9.47 (As of Today)
View and export this data going back to 2018. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Guardant Health's share price is $36.49. Guardant Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $3.85. Hence, Guardant Health's PS Ratio for today is 9.47.

Good Sign:

Guardant Health Inc stock PS Ratio (=9.68) is close to 5-year low of 9.32

The historical rank and industry rank for Guardant Health's PS Ratio or its related term are showing as below:

GH' s PS Ratio Range Over the Past 10 Years
Min: 9.32   Med: 36.06   Max: 75.25
Current: 9.76

During the past 6 years, Guardant Health's highest PS Ratio was 75.25. The lowest was 9.32. And the median was 36.06.

GH's PS Ratio is ranked worse than
79.32% of 237 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.07 vs GH: 9.76

Guardant Health's Revenue per Sharefor the three months ended in Mar. 2022 was $0.94. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $3.85.

Warning Sign:

Guardant Health Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Guardant Health was 28.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 7.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 56.70% per year.

During the past 6 years, Guardant Health's highest 3-Year average Revenue per Share Growth Rate was 87.80% per year. The lowest was 7.40% per year. And the median was 61.00% per year.

Back to Basics: PS Ratio


Guardant Health PS Ratio Historical Data

The historical data trend for Guardant Health's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PS Ratio
Premium Member Only - 12.61 33.03 43.82 27.12

Guardant Health Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.85 38.56 36.69 27.12 17.20

Competitive Comparison

For the Diagnostics & Research subindustry, Guardant Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Guardant Health PS Ratio Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's PS Ratio distribution charts can be found below:

* The bar in red indicates where Guardant Health's PS Ratio falls into.



Guardant Health PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Guardant Health's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=36.49/3.852
=9.47

Guardant Health's Share Price of today is $36.49.
Guardant Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.85.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Guardant Health  (NAS:GH) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Guardant Health PS Ratio Related Terms

Thank you for viewing the detailed overview of Guardant Health's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health Business Description

Guardant Health logo
Industry
Traded in Other Exchanges
Address
505 Penobscot Drive, Redwood City, CA, USA, 94063
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
Executives
Talasaz Amirali director, officer: Chairman, President and COO 18 ISABELLA AVENUE ATHERTON CA 94027
Kaul Samir director C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025
Meresman Stanley J director 2071 HUNTINGTON LANE LOS ALTOS CA 94024
Svf Bluebird (cayman) Ltd 10 percent owner C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Svf Enterprise (cayman) Ltd 10 percent owner C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Sb Investment Advisers (uk) Ltd 10 percent owner 69 GROSVENOR STREET LONDON X0 W1K 3JP
Softbank Vision Fund (aiv M1) L.p. 10 percent owner 251 LITTLE FALLS DRIVE WILMINGTON DE 19808
Svf Endurance (cayman) Ltd 10 percent owner C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008
Clark Ian T director SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080
Eltoukhy Helmy director, officer: Chief Executive Officer 2 BARRY LANE ATHERTON CA 94027
Bertocci Derek A officer: Chief Financial Officer 3070 ORCHARD DRIVE SAN JOSE CA 95134
Saia John G. officer: See Remarks C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063
Gadde Vijaya director C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103
Jallal Bahija director 120 MONUMENT CIRCLE INDIANAPOLIS IN 46204
Nishar Dipchand director C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043

Guardant Health Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)